doi: 10.1016/s0014-5793(01)03302-6
P.HungM.WangW.NguyenJ.GilbertP
The US Food and Drug Administration (FDA) approval for weight management of the first-generation glucagon-like peptide 1 (GLP-1) receptor agonists (RA) liraglutide in 2014 followed by two more potent GLP-1 based therapies (GBT), semaglutide (GLP-1RA) in 2021 and tirzepatide (dual GLP-1/gastric inhibitory polypeptide RA) in 2023 [8,9] have led to a paradigm shift in the management of health conditions related to obesity
nevertheless, their distinct N-terminal residuesglycine, alanine, or aspartic acidmay modestly affect stability and biological efficacy
Why I Recommend 5Strands Helps identify food sensitivities and intolerances Simple, noninvasive at-home testing Eliminates guesswork around nutrition and digestion Supports personalized wellness and gut health This is a helpful starting point for people trying to better understand digestion, inflammation, and energy issues
Patients taking semaglutide 2.4mg lost an average of 14.9% of their body weight over 68 weeks, with 86.4% achieving at least 5% weight loss and nearly half losing 15% or more
